These findings provide novel evidence for the anti-metastatic and anti-angiogenic properties of angelol-a in human cervical cancer cells through modulation of the ERK pathway and targeting the miR-29a-3p/MMP2/VEGFA axis. Here, MMP2 is linked to cervical carcinoma.